Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pitavastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 5/20 | 0.85 |
| ▸ | PDE4D | Q08499 | 3/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | RXRA | P19793 | 3/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.54 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.54 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | CCKAR | P32238 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.54 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pitavastatin SCHEMBL1582325 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL6068297 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL2878734 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL13278896 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL6068293 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL2878610 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL13278902 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL13278898 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL2878736 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA | |
| Pitavastatin SCHEMBL3369 | 1.00 | PDE4D (1.00) | PDE4DNR4A2NR1I2HMGCRRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1623978-B1 | METHOD FOR PRODUCING ETHYL (3R, 5S, 6E)-7-[2-CYCLOPROPYL-4-( 4-FLUOROPHENYL)QUINOLINE-3-YL]-3,5-DIHYDROXY-6-HEPTENOATE | DAICEL CHEM (JP) | 2010-08-11 | — | — | EP | claimed |
| EP-1391455-B1 | PROCESS FOR PREPARATION OF A QUINOLINECARBALDEHYDE | DAICEL CHEM (JP) | 2010-04-14 | — | — | EP | claimed |
| US-7193086-B2 | Process for preparation of a quinolinecarbaldehyde | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-03-20 | — | — | US | claimed |
| US-20040147750-A1 | Process for preparation of a quinolinecarbaldehyde | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2004-07-29 | — | — | US | claimed |
| EP-1391455-A1 | PROCESS FOR PREPARATION OF A QUINOLINECARBALDEHYDE | Daicel Chemical Industries, Ltd. (JP) | 2004-02-25 | — | — | EP | claimed |
| EP-0747341-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE MEVALONOLACTONE COMPOUNDS | DAICEL CHEM (JP) | 2002-05-22 | — | — | EP | claimed |
| EP-4072552-A1 | CHEMOTHERAPEUTIC DRUG IMPLANT | Extruded Pharmaceuticals Ltd (GB) | 2022-10-19 | — | — | EP | disclosed |
| WO-2015024925-A1 | MODULATORS OF THE UNCONVENTIONAL SECRETORY PATHWAY FOR USE IN THE TREATMENT OF ALEXANDER DISEASE | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2015-02-26 | — | — | WO | disclosed |
| EP-2751081-A1 | POLYMORPHIC FORM OF PITAVASTATIN CALCIUM | Farma GRS, d.o.o. (SI) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013037838-A1 | POLYMORPHIC FORM OF PITAVASTATIN CALCIUM | FARMA GRS, D.O.O. (SI) | 2013-03-21 | — | — | WO | disclosed |
| CN-102321019-A | The crystalline form of quinoline compound and working method thereof | NISSAN CHEMICAL IND LTD | 2012-01-18 | — | — | CN | disclosed |
| EP-1375485-B1 | METHOD FOR PREPARING 7-QUINOLINYL-3,5-DIHYDROXYHEPT-6-ENOATE | NISSAN CHEMICAL IND LTD (JP) | 2011-04-20 | — | — | EP | disclosed |
| CN-1946384-B | Statins for the treatment of ocular hypertension and glaucoma | ALCON INC | 2011-04-20 | — | — | CN | disclosed |
| WO-2005046725-A1 | NOVEL COMBINATION CONTAINING A STIMULATOR OF SOLUBLE GUANYLATE CYCLASE AND A LIPID-LOWERING SUBSTANCE | BAYER HEALTHCARE AG (DE) | 2005-05-26 | — | — | WO | disclosed |
| US-20050014947-A1 | Method for preparing a 7-quinolinyl-3, 5-dihydroxyhept-6-enoate | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| US-20040147750-A1 | Process for preparation of a quinolinecarbaldehyde | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1391455-A1 | PROCESS FOR PREPARATION OF A QUINOLINECARBALDEHYDE | Daicel Chemical Industries, Ltd. (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1375485-A1 | METHOD FOR PREPARING 7-QUINOLINYL-3,5-DIHYDROXYHEPT-6-ENOATE | Nissan Chemical Industries, Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-0747341-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE MEVALONOLACTONE COMPOUNDS | DAICEL CHEM (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-0747341-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE MEVALONOLACTONE COMPOUND | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014947-A1 | Method for preparing a 7-quinolinyl-3, 5-dihydroxyhept-6-enoate | QDPR, DHCR7, GHRHR | HMGCR 584/4885PDE4D 747/4885NR4A2 1857/4885 |
| US-20040147750-A1 | Process for preparation of a quinolinecarbaldehyde | OGDH, DOHH, CBR3 | HMGCR 430/4885PDE4D 1723/4885NR4A2 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.